M Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med
2000;1603365- 3373Link to Article
DT Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. Am J Med.
79S- 84SLink to Article
J Management of chronic hepatitis C in HIV-infected patients. AIDS.
1999;13539- 546Link to Article
et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med.
1998;338853- 860Link to Article
et al. Epidemiology of human immunodeficiency virus–associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis.
S5- S14Link to Article
J Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol.
1999;31119- 123Link to Article
LB Natural history of hepatitis C. Hepatology.
21S- 28SLink to Article
LB Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis.
2000;2017- 35Link to Article
et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis.
2001;32492- 497Link to Article
et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Clin Infect Dis.
2001;321487- 1493Link to Article
M Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis.
2001;331793- 1795Link to Article
et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy: Aquitane Cohort France, 1998-1999. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections February 4-8, 2001 Chicago, IllAvailable at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/299.htm
. Accessed April 23, 2001. Abstract 299
et al. Liver failure from HCV as the current leading cause of death in HIV-infected patients in Northern Italy. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections February 4-8, 2001 Chicago, IllAvailable at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/573.htm
. Accessed April 23, 2001. Abstract 573
D Death in HIV-infected inpatients in the HAART era: an evaluation of mortality in an inner-city hospital. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections February 4-8, 2001 Chicago, IllAvailable at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/300.htm
. Accessed April 23, 2001. Abstract 300
et al. Extrapolating long-term HIV/AIDS survival in the post-HAART era. Program and abstracts of the 39th International Conference on Antimicrobial Agents and Chemotherapy September 26-29, 1999 San Francisco, CalifAbstract 1158
et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr.
2000;24211- 217Link to Article
J Impact of chronic viral hepatitis on hospital admission and mortality in HIV-infected patients. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections February 4-8, 2001 Chicago, IllAvailable at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/297.htm
. Accessed April 23, 2001). Abstract 297
ER Outcome of hospital care of liver disease associated with hepatitis C in the United States. Hepatology.
2001;33201- 206Link to Article
C The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol.
1994;87555- 561Link to Article
et al. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS.
1995;91131- 1136Link to Article
et al. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. Virology.
1998;244504- 512Link to Article
et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis.
1996;174690- 695Link to Article
JJ Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus: the Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr. 1993;6602- 610
et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis.
2001;33562- 569Link to Article
T Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. Hum Pathol.
2000;3169- 74Link to Article
et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol.
1998;28945- 950Link to Article
SH Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis.
2001;1831112- 1115Link to Article
et al. for the Multivirc Group, Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology.
1999;301054- 1058Link to Article
et al. Anti-protease inhibitor therapy decreases the liver fibrosis progression rate in HIV-HCV coinfected patients [abstract]. Hepatology. 1999;30362A
et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet.
1997;3501425- 1431Link to Article
et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. Am J Gastroenterol. 1997;921130- 1134
CM Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus–positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis.
1999;1791254- 1258Link to Article
et al. Hepatitis virus coinfections, antiretrovirals hepatotoxicity, and risk of death in HIV-infected persons: prospective cohort study. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections February 4-8, 2001 Chicago, IllAvailable at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/576.htm
. Accessed April 23, 2001. Abstract 576
et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis.
1995;14949- 953Link to Article
et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol.
1997;261- 5Link to Article
et al. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology.
1994;201152- 1155Link to Article
S Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis.
1996;231117- 1125Link to Article
et al. for the Hemophilia Growth and Development Study, Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis.
2001;183589- 595Link to Article
DL Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis.
S77- S84Link to Article
et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet.
2000;3561800- 1805Link to Article
et al. Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus–positive patients. J Viral Hepat.
2000;7302- 308Link to Article
et al. Does HCV coinfection modify survival in HIV-infected patients on combinations of antiretrovirals? Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections February 4-8, 2001 Chicago, IllAvailable at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/321.htm
Accessed April 23, 2001. Abstract 321
C Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ.
2001;3231151- 1155Link to Article
et al. for the International Hepatitis Interventional Therapy Group (IHIT), Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet.
1998;3521426- 1432Link to Article
O Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet.
1998;35183- 87Link to Article
et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med.
1998;3391485- 1492Link to Article
P Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess. 2000;41- 67
et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomised trials. JAMA.
2001;285193- 199Link to Article
et al. for the Eurohep Study Group for Viral Hepatitis, Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology.
1999;117408- 413Link to Article
SGfor the International Hepatitis Interventional Therapy Group, Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am J Gastroenterol. 2000;951524- 1530
SG Cost-effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. Am J Med.
2000;108366- 373Link to Article
GL Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med.
1997;127855- 865Link to Article
KM Cost effectiveness of interferon alpha-2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology.
1999;301318- 1324Link to Article
et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med.
1997;127866- 874Link to Article
JB Cost-effectiveness of treatments for chronic hepatitis C. Am J Med.
74S- 78SLink to Article
RS Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. Ann Intern Med.
2000;133665- 675Link to Article
D Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol.
2001;36870- 876Link to Article
R Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol.
2000;33651- 658Link to Article
EL A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol.
2001;13483- 488Link to Article
Jr Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C. Hepatology.
2000;31807- 808Link to Article
et al. Peg-interferon alfa-2a in patients with chronic hepatitis C. N Engl J Med.
2000;3431666- 1672Link to Article
et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology.
2001;33433- 438Link to Article
et al. for the Hepatitis C Intervention Therapy Group, Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther.
2000;68556- 567Link to Article
et al. for the Hepatitis C Intervention Therapy Group, A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology.
2000;32647- 653Link to Article
J Antiviral therapy for patients with chronic hepatitis C. Semin Liver Dis.
2000;20185- 199Link to Article
et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology.
2001;34395- 403Link to Article
et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet.
2001;358958- 965Link to Article
J Clinical guidelines on the management of hepatitis C. Gut.
I1- I21Link to Article
European Association for Study of the Liver, EASL International Consensus Conference on hepatitis C. J Hepatol.
3- 8Link to Article
Not Available, Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998;47
JH Hepatitis C: the clinical spectrum of disease. Hepatology.
1997;2615S- 20SLink to Article
N Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS clinical trials Group. Clin Infect Dis.
2002;34831- 837Link to Article
MC Cost-effectiveness in Health and Medicine. New York, NY Oxford University Press1996;
Centers for Disease Control and Prevention, 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Recomm Rep. 1999;48
1- 5961- 66
O Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver.
1993;13274- 278Link to Article
et al. A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan: comparison between posttransfusion and sporadic patients. J Hepatol.
1994;21244- 249Link to Article
et al. for the National Heart, Lung, and Blood Institute Study Group, Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med.
1992;3271906- 1911Link to Article
S Natural history of chronic hepatitis C. Ital J Gastroenterol Hepatol. 1999;3128- 44
J Histological evolution of chronic hepatitis C: factors related to progression. Liver.
1994;14265- 269Link to Article
K Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up. Scand J Gastroenterol.
1992;27812- 816Link to Article
et al. The importance of cofactors in the histologic progression of minimal and mild chronic hepatitis C. Liver.
1997;17215- 223Link to Article
T Natural course of chronic hepatitis C. Am J Gastroenterol. 1993;88240- 243
et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol.
1992;16273- 281Link to Article
et al. The long-term pathological evolution of chronic hepatitis C. Hepatology.
1996;231334- 1340Link to Article
K The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology.
1996;23695- 699Link to Article
et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology.
1997;112463- 472Link to Article
et al. Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis: survival and prognostic factors. Scand J Gastroenterol.
1989;24999- 1006Link to Article
et al. Determinants of outcome of compensated hepatitis C virus–related cirrhosis. Hepatology.
1998;271435- 1440Link to Article
et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med.
1993;3281797- 1801Link to Article
et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology.
1987;7122- 128Link to Article
et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol. 1997;9266- 72
Not Available, SEER Cancer Statistics Review, 1973-1994. Surveillance, Epidemiology, and End Results Web site. Available at: http://www-seer.ims.nci.nih.gov/
. Accessed July 7, 2001
et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol. 1993;88514- 519
National Center for Health Statistics, Vital Statistics of the United States, 1992. Washington, DC Public Health Service1996;
et al. Survival from early, intermediate, and late stages of HIV infection. JAMA.
1996;2751329- 1334Link to Article
et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med.
2001;344824- 831Link to Article
et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med.
2001;134440- 450Link to Article
et al. Prophylaxis for human immunodeficiency virus–related Pneumocystis carinii
pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med
2002;162921- 928Link to Article
Not Available, Multicenter AIDS Cohort Study (MACS) Public Dataset: Release P04. Springfield, Va National Technical Information Service1995;
et al. Statistical analysis of the stages of HIV infection using a Markov model. Stat Med.
1989;8831- 843Link to Article
et al. Physicians' preference values for hepatitis C health states and antiviral therapy: a survey. BMC Gastroenterol. 2001;1- 6
MC Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making.
2002;2227- 38Link to Article
et al. for the HIV Cost and Services Utilization Study Consortium, The care of HIV-infected adults in the United States. N Engl J Med.
1998;3391897- 1904Link to Article
Q Multiattribute utility function for a comprehensive health status classification system: Health Utilities Index Mark 2. Med Care.
1996;34702- 722Link to Article
K Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol.
1998;511115- 1128Link to Article
HC Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology.
1998;27209- 212Link to Article
GR Hepatitis C virus infection: quality of life and side effects of treatment. J Hepatol.
250- 254Link to Article
JMfor the Consensus Interferon Study Group, Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology.
1999;29264- 270Link to Article
GL Health-related quality of life in chronic hepatitis C: impact of disease and treatment. Hepatology.
1999;30550- 555Link to Article
Jr Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis. 1999;19
et al. The effects of interferon alpha-2b in combination with ribavirin on health-related quality of life and work productivity. J Hepatol.
2001;34140- 147Link to Article
G Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol.
2001;96579- 583Link to Article
et al. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol.
2001;962199- 2205Link to Article
D Treatment of hepatitis C virus and HIV co-infections. Clin Liver Dis.
2001;51045- 1061Link to Article
et al. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol.
2001;96170- 178Link to Article
et al. Therapy with pegylated interferon alfa-2a significantly enhances quality of life compared with standard interferon [abstract]. Paper presented at: the American Association for the Study of Liver Diseases October 27-31, 2000 Dallas, Tex
M Health profile preferences of hepatitis C patients. Dig Dis Sci.
2000;45345- 350Link to Article
N The impact of diagnosis of hepatitis C virus on quality of life. Hepatology.
1999;301299- 1301Link to Article
AS Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol.
2001;962737- 2744Link to Article
SG Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA.
1998;2802088- 2093Link to Article
C Health state utilities and quality of life in hepatitis C patients. Paper presented at: 23rd Annual Meeting of the Society for Medical Decision Making October 21-24, 2001 San Diego, Calif
U Health related quality of life in chronic hepatitis C patients: a comparison of different utility assessment methods. Paper presented at: 23rd Annual Meeting of the Society for Medical Decision Making October 21-24, 2001 San Diego, Calif
Not Available, 2000 Drug Topics: Red Book. Montvale, NJ Medical Economics2000;
Bureau of Labor Statistics, Statistical Abstract of the United States: Consumer Price Index—All Urban Consumers. Washington, DC Bureau of the Census2000;
T Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health.
2000;901562- 1569Link to Article
M Costs of hepatitis C. Arch Intern Med
2001;1612231- 2237Link to Article
AIDS treatment data network, Hepatitis C Action and Advocacy Coalition Web site. Available at: http://www.atdn.org
. Accessed December 28, 2001
GC The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust. 1994;160268- 272
Not Available, 2000 Clinical Diagnostic Laboratory Fee Schedule Public Use File. Baltimore, MD Health Care Financing Administration2000;
et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med.
2001;344817- 823Link to Article
Not Available, AIDS Cost and Services Utilization Survey: Public Use Tapes 4 and 5. Springfield, Va National Technical Information Service1994;No. PB94189891
SD Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol.
1997;1654- 62Link to Article
KA The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med.
1999;13097- 107Link to Article
et al. for the Study Group of the Association of Italian Hemophilia Centers, A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C. Blood. 1998;911173- 1177
et al. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis.
1992;165723- 726Link to Article
MFfor the French Multicenter Study Group, Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? a French multicenter prospective study. J Hepatol.
2000;321003- 1010Link to Article
et al. Efficacy and safety of alpha interferon therapy for chronic hepatitis C in HIV patients [abstract]. Hepatology. 1994;20162A
et al. Interferon treatment for chronic hepatitis C infection in hemophiliacs: influence of virus load, genotype, and liver pathology on response. Blood. 1996;871704- 1709
et al. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS.
2000;14839- 844Link to Article
et al. Treatment of chronic hepatitis C with interferon-alpha in patients infected with the human immunodeficiency virus. Hepatogastroenterology. 1995;42528- 534
et al. Interferon + ribavirin in HIV+ patients with chronic hepatitis C. Paper presented at: 7th Conference on Retroviruses and Opportunistic Infections January 30-Feberuary 2, 2000 San Francisco, CalifAvailable at: http://www.retroconference.org/2000/abstracts/284.htm
. Accessed April 23, 2001. Abstract 284
et al. for the Hepatitis HIV Spanish Study Group, High rate of co-infection with different hepatitis C virus subtypes in HIV-infected intravenous drug addicts in Spain. J Hepatol.
1995;22598- 599Link to Article
et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut.
2000;47694- 697Link to Article
M Advances in hepatitis C: sero-epidemiology and natural history. J Gastroenterol Hepatol.
1992;7549- 550Link to Article
et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology.
1990;12671- 675Link to Article
et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology.
1998;281687- 1695Link to Article
RL Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med.
1995;3321463- 1466Link to Article
CF The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs intravenous drug use. Hepatology.
1993;181338- 1343Link to Article
et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol.
1990;1069- 76Link to Article
et al. Non-A, non-B posttransfusion hepatitis: comparing C and non-C hepatitis. Hepatology.
1993;17361- 365Link to Article
LB The natural history of hepatitis C-A quandary. Hepatology.
1998;281710- 1712Link to Article
Eand the Irish Hepatology Research Group, Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med.
1999;3401228- 1233Link to Article
R The natural history of hepatitis C: clinical experiences. J Hepatol.
1996;2452- 54Link to Article
et al. 45-Year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med.
2000;132105- 111Link to Article
C The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis.
1997;175164- 168Link to Article
et al. Hepatitis C is more severe in drug users with human immunodeficiency virus infection. J Viral Hepat.
2000;7297- 301Link to Article
D The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol.
1996;94746- 752Link to Article
H Interactions between the human immunodeficiency virus and hepatitis C virus. Rev Med Interne.
1998;19885- 891Link to Article
D Hepatitis C in the HIV (human immunodeficiency virus) Atlanta VA (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis.
1999;29150- 154Link to Article
JM Cost-effectiveness of screening for HPV-induced anal squamous intraepithelial lesions in homosexual men. Am J Med.
2000;108634- 641Link to Article
et al. for the Study 006 Team, Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med.
1999;3411865- 1873Link to Article
et al. for the AIDS Clinical Trials Group 320 Study Team, A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med.
1997;337725- 733Link to Article
et al. for the CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS, A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS.
2000;14F83- F93Link to Article
RD Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med.
1999;13181- 87Link to Article
et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA.
1998;28035- 41Link to Article
et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial: Italy, The Netherlands, Canada and Australia Study. JAMA.
1998;279930- 937Link to Article
RD Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA.
2000;28374- 80Link to Article
et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr.
2001;28114- 123Link to Article
et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS.
2000;142895- 2902Link to Article
J Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS.
1998;121112- 1113Link to Article
R The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS.
2000;14463- 465Link to Article
et al. Hepatotoxicity in the US Adult AIDS Clinical Trial Group [abstract]. Gastroenterology. 2001;120- 283
A The impact of HIV therapy with HAART on HCV disease in HIV/HCV co-infection. Paper presented at: Digestive Disease Week 2001 conference May 20-23, 2001 Atlanta, GaAbstract 1894
et al. Efficacy and tolerance of IFN and ribavirin for chronic hepatitis C in HIV-infected patients. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections February 4-8, 2001 Chicago, IllAvailable at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/574.htm
. Accessed April 23, 2001. Abstract 574
DA Adverse effects of antiretroviral therapy. Lancet.
2000;3561423- 1430Link to Article
R Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis.
S96- S116Link to Article
et al. Can HCV affect the efficacy of anti-HIV treatment? Arch Virol.
2000;145937- 944Link to Article
C Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin Infect Dis.
2001;331579- 1585Link to Article
N Comparison of addictive and multiplicative utility functions to predict the utilities of combined health states. Paper presented at: 23rd Annual Meeting of the Society for Medical Decision Making October 21-24, 2001 San Diego, Calif
ML HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health.
2000;901100- 1111Link to Article
GW Social preferences for health states: an empirical evaluation of three measurement techniques. Socioecon Planning Sci. 1976;10128- 136
DM Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci.
1997;422482- 2486Link to Article
et al. Assessing health related quality of life in chronic hepatitis C using the sickness impact profile. Clin Ther. 1994;16334- 343